64 related articles for article (PubMed ID: 23313758)
1. Mechanisms of epoxyeicosatrienoic acids to improve cardiac remodeling in chronic renal failure disease.
Zhang K; Wang J; Zhang H; Chen J; Zuo Z; Wang J; Huang H
Eur J Pharmacol; 2013 Feb; 701(1-3):33-9. PubMed ID: 23313758
[TBL] [Abstract][Full Text] [Related]
2. Apocynin improving cardiac remodeling in chronic renal failure disease is associated with up-regulation of epoxyeicosatrienoic acids.
Zhang K; Liu Y; Liu X; Chen J; Cai Q; Wang J; Huang H
Oncotarget; 2015 Sep; 6(28):24699-708. PubMed ID: 26322503
[TBL] [Abstract][Full Text] [Related]
3. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning.
Gauthier KM; Yang W; Gross GJ; Campbell WB
J Cardiovasc Pharmacol; 2007 Dec; 50(6):601-8. PubMed ID: 18091575
[TBL] [Abstract][Full Text] [Related]
4. Epoxyeicosatrienoic acids--novel mechanism and pharmacological therapy of chronic renocardiac syndrome.
Huang H; Chen J; Lin T; Wang T; Tang Y; Dong Y; Wang J
Med Hypotheses; 2011 Apr; 76(4):550-2. PubMed ID: 21333454
[TBL] [Abstract][Full Text] [Related]
5. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells.
Katragadda D; Batchu SN; Cho WJ; Chaudhary KR; Falck JR; Seubert JM
J Mol Cell Cardiol; 2009 Jun; 46(6):867-75. PubMed ID: 19285984
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment with epoxyeicosatrienoic acids modulates insulin signaling and prevents insulin resistance in hepatocytes.
Skepner JE; Shelly LD; Ji C; Reidich B; Luo Y
Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):3-8. PubMed ID: 21040800
[TBL] [Abstract][Full Text] [Related]
7. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
8. Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Larsen BT; Campbell WB; Gutterman DD
Trends Pharmacol Sci; 2007 Jan; 28(1):32-8. PubMed ID: 17150260
[TBL] [Abstract][Full Text] [Related]
9. Cyclic AMP-dependent modulation of cardiac L-type Ca2+ and transient outward K+ channel activities by epoxyeicosatrienoic acids.
Xiao YF
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):11-8. PubMed ID: 17164128
[TBL] [Abstract][Full Text] [Related]
10. The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling.
Lai J; Chen C
Front Physiol; 2021; 12():642470. PubMed ID: 33716791
[TBL] [Abstract][Full Text] [Related]
11. [Endogenous protective effects of arachidonic acid epoxygenase metabolites, epoxyeicosatrienoic acids, in cardiovascular system].
He ZW; Wang B; Chen C; Shi ZQ; Wang DW
Sheng Li Xue Bao; 2021 Aug; 73(4):617-630. PubMed ID: 34405218
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of epoxyeicosatrienoic acids on volume-activated chloride channels in rat mesenteric arterial smooth muscle.
Yang C; Kwan YW; Seto SW; Leung GP
Prostaglandins Other Lipid Mediat; 2008 Dec; 87(1-4):62-7. PubMed ID: 18812234
[TBL] [Abstract][Full Text] [Related]
13. TVP1022 attenuates cardiac remodeling and kidney dysfunction in experimental volume overload-induced congestive heart failure.
Abassi ZA; Barac YD; Kostin S; Roguin A; Ovcharenko E; Awad H; Blank A; Bar-Am O; Amit T; Schaper J; Youdim M; Binah O
Circ Heart Fail; 2011 Jul; 4(4):463-73. PubMed ID: 21558446
[TBL] [Abstract][Full Text] [Related]
14. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
15. Epoxyeicosatrienoic acids, cell signaling and angiogenesis.
Fleming I
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):60-7. PubMed ID: 17164133
[TBL] [Abstract][Full Text] [Related]
16. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
[TBL] [Abstract][Full Text] [Related]
17. Role of apoptosis in remodeling after myocardial infarction.
Takemura G; Fujiwara H
Pharmacol Ther; 2004 Oct; 104(1):1-16. PubMed ID: 15500905
[TBL] [Abstract][Full Text] [Related]
18. Effects of epoxyeicosatrienoic acids on 86Rb uptake in renal epithelial cells.
Staudinger R; Escalante B; Schwartzman ML; Abraham NG
J Cell Physiol; 1994 Jul; 160(1):69-74. PubMed ID: 8021300
[TBL] [Abstract][Full Text] [Related]
19. Cardiac fibroblasts: at the heart of myocardial remodeling.
Porter KE; Turner NA
Pharmacol Ther; 2009 Aug; 123(2):255-78. PubMed ID: 19460403
[TBL] [Abstract][Full Text] [Related]
20. An "I" on cardiac hypertrophic remodelling: imidazoline receptors and heart disease.
Mukaddam-Daher S
Can J Cardiol; 2012; 28(5):590-8. PubMed ID: 22483786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
